{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:40:36Z","timestamp":1792453236510,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016615","name":"Curing Kids Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children&apos;s Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA176745"],"award-info":[{"award-number":["CA176745"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA204639"],"award-info":[{"award-number":["CA204639"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA066996"],"award-info":[{"award-number":["CA066996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA206963"],"award-info":[{"award-number":["CA206963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["511811315"],"award-info":[{"award-number":["511811315"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:40:55Z","timestamp":1755236455000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Menin inhibition for the treatment of acute leukemia"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-9104","authenticated-orcid":false,"given":"Daniela V.","family":"Wenge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.seminhematol.2025.08.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35834","article-title":"Top advances of the year: acute myeloid leukemia","volume":"131","author":"Thakur","year":"2025","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0003","unstructured":"Kura Oncology receives breakthrough therapy designation for ziftomenib in NPM1-mutant AML. 2024. (cited 04-11-2024) available from: https:\/\/ir.kuraoncology.com\/news-releases\/news-release-details\/kura-oncology-receives-breakthrough-therapy-designation"},{"issue":"5311","key":"10.1053\/j.seminhematol.2025.08.001_bib0004","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.08.001_bib0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.001_bib0006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.08.001_bib0007","first-page":"1166","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Ca Disc"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0008","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.08.001_bib0009","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.001_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.08.001_bib0011","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"7954","key":"10.1053\/j.seminhematol.2025.08.001_bib0012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"7954","key":"10.1053\/j.seminhematol.2025.08.001_bib0013","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0014","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.08.001_bib0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer cell"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.08.001_bib0016","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Ca"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0017","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.leu.2402135","article-title":"An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners","volume":"15","author":"Huret","year":"2001","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.08.001_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.08.001_bib0020","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2004-07-2683","article-title":"Therapy-related acute myeloid leukemia\u2013like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion","volume":"105","author":"Libura","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.08.001_bib0022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.molmed.2004.08.005","article-title":"MLL: a histone methyltransferase disrupted in leukemia","volume":"10","author":"Hess","year":"2004","journal-title":"Trends Mol Med"},{"issue":"40","key":"10.1053\/j.seminhematol.2025.08.001_bib0023","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1038\/sj.onc.1204639","article-title":"Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins","volume":"20","author":"Ayton","year":"2001","journal-title":"Oncogene"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.08.001_bib0024","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1097-2765(02)00741-4","article-title":"MLL targets SET domain methyltransferase activity to hox gene promoters","volume":"10","author":"Milne","year":"2002","journal-title":"Mol Cell"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.08.001_bib0026","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.08.001_bib0027","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.001_bib0028","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.001_bib0029","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.08.001_bib0031","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/blood-2014-04-570929","article-title":"NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report","volume":"124","author":"Ostronoff","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.08.001_bib0032","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","article-title":"Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia","volume":"33","author":"McNeer","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0033","first-page":"863","article-title":"NUP98 Fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis","volume":"30","author":"Xu","year":"2016","journal-title":"Ca Cell"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0034","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.08.001_bib0035","first-page":"202","article-title":"UBTF-internal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid leukemia","volume":"62","author":"Kaburagi","year":"2023","journal-title":"Genes Chromos Ca"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0036","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41375-023-01906-z","article-title":"UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia","volume":"37","author":"Duployez","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0037","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-023-00858-y","article-title":"UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome","volume":"13","author":"Georgi","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.08.001_bib0038","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary data on a phase 1\/2A first in Human study of the Menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0040","first-page":"1278","article-title":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","volume":"110","author":"Hogeling","year":"2020","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-Human Phase 1\/2 study of the Menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0042","unstructured":"Kura Oncology doses first patient in phase 1 clinical trial of Menin-MLL inhibitor KO-539 in acute myleoid leukemia. 2019, available from: https:\/\/ir.kuraoncology.com\/news-releases\/news-release-details\/kura-oncology-doses-first-patient-phase-1-clinical-trial-menin, 09-16-2019."},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0043","unstructured":"Syndax announces first patient dosed in phase 1\/2 AUGMENT-101 trial of SNDX-5613 for the treatment of adults with relapsed\/refractory acute leukemias. 2019, available from: https:\/\/ir.syndax.com\/news-releases\/news-release-details\/syndax-announces-first-patient-dosed-phase-12-augment-101-trial, 11-06-2019."},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0044","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0045","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1182\/blood-2023-189036","article-title":"Revumenib maintenance therapy following Revumenib-induced remission and transplant","volume":"142","author":"Zucenka","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0046","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.08.001_bib0047","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0048","doi-asserted-by":"crossref","first-page":"57-","DOI":"10.1182\/blood-2023-172422","article-title":"A first-in-Human phase 1 study of the Menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0049","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2024-198959","article-title":"A first-in-Human phase 1\/2 study of the Menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0050","unstructured":"Expert systems celebrates a milestone with Eilean Therapeutics: initiation of first-in-patient trial of balamenib, a selective best-in-class Menin inhibitor. 2025, available from: https:\/\/www.expertsystems.inc\/news\/expert-systems-celebrates-a-milestone-with-eilean-therapeutics-initiation-of-first-in-patient-trial-of-balamenib-a-selective-best-in-class-menin-inhibito, 03-13-2025."},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0051","first-page":"64","article-title":"The novel menin inhibitor ZE63-0302 has an impressive safety profile and unique chemistry that suggests improved efficacy against resistance mutations","volume":"2024","author":"Hertlein EA-A","year":"2024","journal-title":"Eur Hematol Assoc (EHA) Hybrid Congress"},{"issue":"6_Supplement","key":"10.1053\/j.seminhematol.2025.08.001_bib0052","doi-asserted-by":"crossref","first-page":"2113-","DOI":"10.1158\/1538-7445.AM2024-2113","article-title":"Abstract 2113: HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearrangedand NPM1mutant acute leukemia in preclinical models","volume":"84","author":"Cheng","year":"2024","journal-title":"Ca Res"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0053","unstructured":"Reference data Daiichi Sankyo. 2024. Consolidated Financial Results for Q4 FY2023, available from: https:\/\/www.daiichisankyo.com\/files\/investors\/library\/quarterly_result\/2023\/FY2023_Q4_Reference_Data_E.pdf, 04-25-2024."},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0054","first-page":"36","article-title":"A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1","volume":"23","author":"Numata","year":"2023","journal-title":"Ca Cell Int"},{"issue":"8_Supplement_1","key":"10.1053\/j.seminhematol.2025.08.001_bib0055","doi-asserted-by":"crossref","first-page":"1419-","DOI":"10.1158\/1538-7445.AM2025-1419","article-title":"Abstract 1419: RCZY-711, a novel, highly potent, and orally bioavailable menin-MLL inhibitor with superior efficacy in preclinical acute leukemia models","volume":"85","author":"Celia","year":"2025","journal-title":"Ca Res"},{"issue":"8_Supplement_1","key":"10.1053\/j.seminhematol.2025.08.001_bib0056","doi-asserted-by":"crossref","first-page":"1752-","DOI":"10.1158\/1538-7445.AM2025-1752","article-title":"Abstract 1752: SY-13380, a novel menin-MLL inhibitor, exhibits efficacy against resistant mutations and anti-tumor activity for MLL-rearranged and NPM1-mutant acute myeloid leukemia in pre-clinical models","volume":"85","author":"Li","year":"2025","journal-title":"Ca Res"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.08.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e15119","article-title":"Examination of in vitro and in vivo antitumor activity of Menin-MLL inhibitor, D0060-319","volume":"41","author":"Xu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0058","doi-asserted-by":"crossref","unstructured":"HitGen Pipeline. Available from: https:\/\/www.hitgen.com\/en\/pipeline.html, 2025.","DOI":"10.5465\/AMPROC.2025.20934abstract"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0059","doi-asserted-by":"crossref","unstructured":"Perner F, Rahnamoun H, Wenge DV, et al. Abstract S125: Non-genetic resistance to menin inhibition in AML is reversible by perturbation of KAT6A. Hemasphere 2023; 57\u20138.","DOI":"10.1097\/01.HS9.0000967412.62331.23"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-24-1517","article-title":"Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia","author":"Gordon","year":"2025","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0061","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.08.001_bib0062","first-page":"258","article-title":"Targeting Menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes","volume":"25","author":"Sparbier","year":"2023","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.08.001_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114901","article-title":"NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML","volume":"43","author":"Heikamp","year":"2024","journal-title":"Cell Rep"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.08.001_bib0064","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.08.001_bib0065","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1182\/blood-2011-07-365320","article-title":"Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype","volume":"118","author":"Grossmann","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2025.08.001_bib0066","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","article-title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders","volume":"122","author":"Damm","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.08.001_bib0067","first-page":"116","article-title":"BCOR and BCORL1 mutations drive epigenetic reprogramming and oncogenic signaling by unlinking PRC1.1 from target genes","volume":"3","author":"Schaefer","year":"2022","journal-title":"Blood Ca Disc"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0068","article-title":"Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis","author":"Xu","year":"2025","journal-title":"bioRxiv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0069","doi-asserted-by":"crossref","first-page":"5995-","DOI":"10.1182\/blood-2024-203466","article-title":"A phase II study of the Menin inhibitor Revumenib in leukemia associated with upregulation of HOX genes: trial in progress","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.08.001_bib0071","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0072","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of Revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0073","doi-asserted-by":"crossref","first-page":"215-","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b study of Menin-KMT2A inhibitor Bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.08.001_bib0074","first-page":"536","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Ca Discov"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.08.001_bib0076","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0077","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/leu.2016.327","article-title":"Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia","volume":"31","author":"Dafflon","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.08.001_bib0078","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","article-title":"MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape","volume":"82","author":"Olsen","year":"2022","journal-title":"Mol Cell"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0079","doi-asserted-by":"crossref","first-page":"4168-","DOI":"10.1182\/blood-2023-190638","article-title":"The clinical Menin inhibitor Ziftomenib and the nuclear export inhibitor Selinexor synergistically inhibit the growth of MLL-r AML","volume":"142","author":"Uddin","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0081","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-24-1772","article-title":"KAT6A and KAT7 histone acetyltransferase complexes are molecular dependencies and therapeutic targets in NUP98-rearranged acute myeloid leukemia","author":"Michmerhuizen","year":"2025","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.08.001_bib0082","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0083","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0084","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41467-025-57544-9","article-title":"Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition","volume":"16","author":"Shi","year":"2025","journal-title":"Nat Commun"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.08.001_bib0085","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0086","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-023-01907-7","article-title":"Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia","volume":"22","author":"Tubio-Santamaria","year":"2023","journal-title":"Mol Cancer"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.08.001_bib0087","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2024-208887","article-title":"Discerning the landscape of Menin inhibitor resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"issue":"7_Supplement","key":"10.1053\/j.seminhematol.2025.08.001_bib0088","doi-asserted-by":"crossref","first-page":"3457-","DOI":"10.1158\/1538-7445.AM2023-3457","article-title":"Abstract 3457: characterization of acquired resistance mutations to menin inhibitors","volume":"83","author":"Perner","year":"2023","journal-title":"Ca Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.08.001_bib0089","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-021-06339-9","article-title":"Reduced menin expression leads to decreased ERalpha expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes","volume":"190","author":"Teinturier","year":"2021","journal-title":"Breast Ca Res Treat"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.08.001_bib0090","article-title":"Combined inhibition of KAT6A\/B and Menin reverses estrogen-receptor-driven gene expression programs in breast cancer","volume":"6","author":"Olsen","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.08.001_bib0091","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-17-0580","article-title":"Pharmacologic inhibition of the Menin-MLL interaction leads to transcriptional repression of PEG10 and blocks hepatocellular carcinoma","volume":"17","author":"Kempinska","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.08.001_bib0092","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1158\/2159-8290.CD-21-0646","article-title":"MOZ and Menin-MLL complexes are complementary regulators of chromatin association and transcriptional output in gastrointestinal stromal tumor","volume":"12","author":"Hemming","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.08.001_bib0093","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14348\/molcells.2021.0206","article-title":"Menin enhances androgen receptor-independent proliferation and migration of prostate cancer cells","volume":"45","author":"Kim","year":"2022","journal-title":"Mol Cells"},{"issue":"12_Supplement","key":"10.1053\/j.seminhematol.2025.08.001_bib0094","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1538-7445.AM2022-2665","article-title":"Abstract 2665: irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors","volume":"82","author":"Law","year":"2022","journal-title":"Ca Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.08.001_bib0095","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/d41573-024-00106-3","article-title":"Menin inhibitors seek to debut as newest targeted therapy for leukaemia","volume":"23","author":"Garber","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2025.08.001_bib0096","first-page":"1","article-title":"Menin: from molecular insights to clinical impact","author":"Brown","year":"2025","journal-title":"Epigenomics"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:30:33Z","timestamp":1769049033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000344"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menin inhibition for the treatment of acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}